Reply: Translation of regenerative technologies into clinical paradigms

Nature Reviews Cardiology

Volumn 11, Issue 9, 2014, Pages 553-554

  Behfar, Atta ^a   Crespo Diaz, Ruben ^a   Terzic, Andre ^a   Gersh, Bernard J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; STAGE SPECIFIC EMBRYO ANTIGEN 1;

BIOLOGICAL THERAPY; CELL POPULATION; HEALTH CARE COST; HEART DISEASE; HUMAN; LETTER; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

CELL- AND TISSUE-BASED THERAPY; HEART DISEASES; HUMANS;

EID: 84906939341     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.9-c2     Document Type: Letter

References (15)

1. Masuda, S. et al. Emerging innovation towards safety in clinical application of ES/iPS cells Nat. Rev. Cardiol. http://dx.doi.org/10.1038/ nrcardio.2014.9-c1.
2. Behfar, A., Crespo-Diaz, R., Terzic, A. & Gersh, B. J. Cell therapy for cardiac repair-lessons from clinical trials. Nat. Rev. Cardiol. 11, 232-246 (2014).
3. Terzic, A., Harper, C. M. Jr., Gores, G. J. & Pfenning, M. A. Regenerative medicine blueprint. Stem Cells Dev. 22 (Suppl. 1), 20-24 (2013).
4. Teluku ntla, K. S., Suncion, V. Y., Schulman, I. H. & Hare, J. M. The advancing field of cell-based therapy: insights and lessons from clinical trials. J. Am. Heart Assoc. 2, e000338 (2013).
5. S,,anganalma th, S. K. & Bolli, R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 113, 810-834 (2013).
6. Assmus , B. et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 309, 1622-1631 (2013).
7. Malli aras, K. et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfun ction). J. Am. Coll. Cardiol. 63, 110-122 (2014).
8. Bartunek, J. et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter rando mized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61, 2329-2338 (2013).
9. Terzic A.,Behfar A Regenerative heart failure therapy headed for optimization. Eur. Heart J. 35 1231-1234 2014).
10. Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L. & Wu, J. C. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998-1004 (2013).
11. Behfar, A. et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J. Exp. Med. 204, 405-420 (2007).
12. Blin, G. et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Invest. 120, 1125-1139 (2010).
13. Smith, A. J. et al. Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells Transl. Med. 1, 709-718 (2012).
14. Menasché , P. et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehu192.
15. Wa ldman, S. A. & Terzic, A. Managing the innovation supply chain to maximize personalized medicine. Clin. Pharmacol. Ther. 95, 113-118 (2014).